title: [De novo cancer after solid organ transplantation: Epidemiology, prognosis and management].
abstract: The risk of cancer after solid organ transplantation is increased by 2.6 compared to overall population. Cancer is currently the third leading cause of death in solid organ transplanted patients, making screening and early management of de novo cancers a major challenge. This increased risk of cancer in this population results from the combination of known environmental risk factors of cancer, comorbidities of transplanted patients, and exposure to chronic immunosuppression. The prognosis of cancer in these patients seems poorer as compared to other cancer patients owing to their comorbidities, the immunosuppression and patient's poorer tolerance to oncologic treatment. Moreover, interactions between immunosuppressive agents and antitumor therapies must be taken into account in the therapeutic strategy. Better knowledge of the specificities of solid organ transplanted patients with de novo cancer is required to improve cancer care in this patient population. This article aims to review the current data available on de novo cancers in solid organ transplanted patients, with a focus on epidemiology, risks factors of de novo cancers, impact of immunosuppressive drugs and oncologic prognosis.
authors.affiliation: Assistance publique-Hôpitaux de Paris, hôpital Henri-Mondor, oncologie médicale, 51, avenue Maréchal-de-Lattre-de-Tassigny, 94010 Créteil, France.
authors.forename: Aude
authors.initials: A
authors.lastname: Guillemin
authors.affiliation: Assistance publique-Hôpitaux de Paris, hôpital Henri-Mondor, oncologie médicale, 51, avenue Maréchal-de-Lattre-de-Tassigny, 94010 Créteil, France; Université Paris Est, faculté de médecine de Créteil, 61, avenue du Général-de-Gaulle, 94010 Créteil, France; Faculté de médecine de Créteil, institut Mondor de recherche biomédicale, Inserm U955 équipe 18, 8, rue du Général-Sarrail, 94010 Créteil, France. Electronic address: benoit.rousseau@aphp.fr.
authors.forename: Benoît
authors.initials: B
authors.lastname: Rousseau
authors.affiliation: Assistance publique-Hôpitaux de Paris, hôpital Henri-Mondor, oncologie médicale, 51, avenue Maréchal-de-Lattre-de-Tassigny, 94010 Créteil, France.
authors.forename: Cindy
authors.initials: C
authors.lastname: Neuzillet
authors.affiliation: Assistance publique-Hôpitaux de Paris, hôpital Henri-Mondor, oncologie médicale, 51, avenue Maréchal-de-Lattre-de-Tassigny, 94010 Créteil, France.
authors.forename: Charlotte
authors.initials: C
authors.lastname: Joly
authors.affiliation: Assistance publique-Hôpitaux de Paris, hôpital Henri-Mondor, oncologie médicale, 51, avenue Maréchal-de-Lattre-de-Tassigny, 94010 Créteil, France.
authors.forename: Helene
authors.initials: H
authors.lastname: Boussion
authors.affiliation: Université Paris Est, faculté de médecine de Créteil, 61, avenue du Général-de-Gaulle, 94010 Créteil, France; Assistance publique-Hôpitaux de Paris, hôpital Henri-Mondor, néphrologie, 51, avenue Maréchal-de-Lattre-de-Tassigny, 94010 Créteil, France.
authors.forename: Philippe
authors.initials: P
authors.lastname: Grimbert
authors.affiliation: Université Paris Est, faculté de médecine de Créteil, 61, avenue du Général-de-Gaulle, 94010 Créteil, France; Chirurgie digestive, hépato-bilio-pancréatique et transplantation hépatique, 51, avenue Maréchal-de-Lattre-de-Tassigny, 94010 Créteil, France.
authors.forename: Philippe
authors.initials: P
authors.lastname: Compagnon
authors.affiliation: Université Paris Est, faculté de médecine de Créteil, 61, avenue du Général-de-Gaulle, 94010 Créteil, France; Assistance publique-Hôpitaux de Paris, hôpital Henri-Mondor, hépatologie, 51, avenue Maréchal-de-Lattre-de-Tassigny, 94010 Créteil, France.
authors.forename: Christophe
authors.initials: C
authors.lastname: Duvoux
authors.affiliation: Assistance publique-Hôpitaux de Paris, hôpital Henri-Mondor, oncologie médicale, 51, avenue Maréchal-de-Lattre-de-Tassigny, 94010 Créteil, France; Université Paris Est, faculté de médecine de Créteil, 61, avenue du Général-de-Gaulle, 94010 Créteil, France.
authors.forename: Christophe
authors.initials: C
authors.lastname: Tournigand
mesh_terms: D000970:Antineoplastic Agents / Q000009:adverse effects; D015897:Comorbidity; D004347:Drug Interactions; D006801:Humans; D007165:Immunosuppression Therapy / Q000009:adverse effects*; D007166:Immunosuppressive Agents / Q000009:adverse effects; D009369:Neoplasms / Q000453:epidemiology / Q000209:etiology* / Q000628:therapy; D016609:Neoplasms, Second Primary / Q000209:etiology; D016377:Organ Transplantation / Q000009:adverse effects*; D011379:Prognosis; D012306:Risk; D014019:Tissue Donors; D014777:Virus Diseases / Q000150:complications
chemical_list: D000970:Antineoplastic Agents; D007166:Immunosuppressive Agents
keywords: Cancer; Epidemiology; Immunosuppresseurs; Immunosuppressive agents; Prognosis; Pronostic; Transplantation; Épidémiologie